---
title: Intraoperative Mitomycin C in Lacrimal Sac Mucocele
nct_id: NCT03176355
overall_status: COMPLETED
phase: NA
sponsor: Minia University
study_type: INTERVENTIONAL
primary_condition: Lacrimal Mucocele
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03176355.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03176355"
ct_last_update_post_date: 2017-06-05
last_seen_at: "2026-05-12T07:32:27.713Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Intraoperative Mitomycin C in Lacrimal Sac Mucocele

**Official Title:** Evaluation of Intraoperative Mitomycin C in Surgical Management of Lacrimal Sac Mucocele

**NCT ID:** [NCT03176355](https://clinicaltrials.gov/study/NCT03176355)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Minia University
- **Conditions:** Lacrimal Mucocele
- **Start Date:** 2011-03-23
- **Completion Date:** 2013-01-07
- **CT.gov Last Update:** 2017-06-05

## Brief Summary

30 patients had lacrimal sac mucocele and dacryocystorhinostomy was done for them with intraoperative mitomycin C was added to decrease postoperative fibrosis and recurrence.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Lacrimal sac mucocele

Exclusion Criteria:

* Paediatric patients (less than 16 years old).
* Previous lacrimal passage procedure.
* Neoplasms as secondary causes of obstruction.
```

## Arms

- **Chronic dacryocystitis patients** (OTHER)

## Interventions

- **Canaliculo- Dacryocystorhinostomy** (PROCEDURE) — Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa

## Primary Outcomes

- **Disappearance of the watering of the eye reported by the patients and by fluorescein disappearance test** _(time frame: 1 month)_ — Patency of the lacrimal passage
- **Disappearance of lacrimal sac swelling** _(time frame: 1 month)_ — No evident swelling in the medial side of the eye

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03176355.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03176355*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*